ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma; A retrospective case report

2 February 2020
This report describes a stage I uveal melanoma patient treated with oncolytic virus Rigvir as an adjuvant therapy.

Read more: https://www.sciencedirect.com/science/article/pii/S245199362030013X

Contacts for Media Inquiries

Rigvir Group
Address: Atlasa street 7C, Riga, Latvia, LV-1026
Phone: +371 67 716 132
E-mail: pr@rigvir.com